Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-24T14:10:20.229Z Has data issue: false hasContentIssue false
  • English
  • Français

Routine treatment pathways of patients with major depression and active suicidal ideation with intent in Italy: interim results from the ARIANNA observational study

Published online by Cambridge University Press:  01 September 2022

M. Pompili ,
A. Bellomo ,
E. Pilotto ,
G. Rosso ,
M. Adami ,
D. Andreis ,
B. Roncari  and
D. Delmonte
M. Pompili
Affiliation:
Sant’Andrea Hospital - Sapienza University of Rome, Department Of Neurosciences, Mental Health And Sensory Organs, Suicide Prevention Center, Rome, Italy
A. Bellomo
Affiliation:
University of Foggia, Department Of Clinical And Experimental Medicine, Psychiatric Unit, Foggia, Italy
E. Pilotto
Affiliation:
ULSS8 Berica - Vicenza Hospital, Department Of Mental Health, Spdc I, Vicenza, Italy
G. Rosso
Affiliation:
San Luigi Gonzaga Hospital - University of Turin, Department Of Neuroscience “rita Levi Montalcini”, Turin, Italy
M. Adami
Affiliation:
Janssen-Cilag SpA, Department Of Medical Affairs - Neuroscience, Cologno Monzese, Italy
D. Andreis
Affiliation:
MediNeos Observational Research - IQVIA, Data Management & Statistics, Modena, Italy
B. Roncari
Affiliation:
MediNeos Observational Research - IQVIA, Clinical Operations, Modena, Italy
D. Delmonte*
Affiliation:
Janssen-Cilag SpA, Department Of Medical Affairs - Neuroscience, Cologno Monzese, Italy
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Major depressive disorder (MDD), especially in case of suicidal risk, is a psychiatric emergency, associated with high patient burden and healthcare resource utilization. Although active and urgent treatment is crucial, little is known on comprehensive care management of this condition in Italy.

Objectives

Here we report the ARIANNA study [NCT04463108] interim results to primarily describe the treatment utilization pathways of patients with MDD and active suicidal ideation with intent in the current clinical practice in Italy.

Methods

This observational prospective cohort study included adult patients with a moderate-to-severe major depressive episode (MDE) and active suicidality from 24 Italian sites. Real-world data on patient characteristics, treatments, clinical outcomes, and healthcare utilization were collected during a 90-day follow-up. Data collection is still ongoing.

Results

Sixty-four evaluable patients were considered for this interim analysis: 41 (64.1%) females, mean [SD] age 46.0 [15.4] years, a concomitant psychiatric diagnosis in 7 (10.9%), and other comorbidities in 26 (40.6%). The baseline mean [SD] MADRS total score was 37.5 [7.2], with severe MDE and prior suicidal behavior in 30 (46.9%) and 21 (32.8%) patients, respectively. Median [25th;75th percentiles] duration of current MDE was 1.1 [0.3;2.1] months. Acute inpatient hospitalization was provided for 43 (67.2%) patients. Antidepressant augmentation with mood stabilizers and/or antipsychotic drugs and optimization were the most frequent early standard-of-care treatment regimens in 32 (53.3%) and 24 (40.0%) patients with available data (N=60), respectively.

Conclusions

Our preliminary results suggest that initial treatment approaches in this critical population are mostly polypharmacological and delivered as inpatient care, with consequent intensive resource utilization.

Disclosure

The ARIANNA study was sponsored by Janssen-Cilag SpA, Italy. DD and MA are employees of Janssen-Cilag SpA. DA and BR are employees of MediNeos S.U.R.L., a company subject to the direction and coordination of IQVIA Solutions HQ Ltd.

Keywords

suicidal ideationmajor depressive disorderreal worldstandard of care
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S147 - S148
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.